The medical management of Cushing's syndrome

Annals of the New York Academy of Sciences

Volumn 970, Issue , 2002, Pages 119-133

  Morris, Damian ^a   Grossman, Ashley ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

5 HT antagonists; Cushing's syndrome; Dopamine agonists; Drug therapy; GABA agonists; Glucocorticoid antagonists; Somatostatin analogues; Steroid biosynthesis inhibitors

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHANE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLUTETHIMIDE; AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BROMOCRIPTINE; CYPROHEPTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; ETOMIDATE; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; IMIDAZOLE DERIVATIVE; INSECTICIDE; KETOCONAZOLE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; RITANSERIN; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID;

ACNE; ADRENAL INSUFFICIENCY; ADRENALIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTASIS; CONFERENCE PAPER; CUSHING DISEASE; DIABETES MELLITUS; DRUG EFFICACY; EDEMA; FEVER; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HIRSUTISM; HUMAN; HYPERALDOSTERONISM; HYPERANDROGENISM; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERTENSION; HYPOKALEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; HYPOURICEMIA; JAUNDICE; LETHARGY; LIBIDO DISORDER; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MORBIDITY; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; RASH; SEDATION; SIDE EFFECT; SURGICAL RISK; VERTIGO; WOUND HEALING;

EID: 0037024509     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04418.x     Document Type: Conference Paper

References (88)

1. Lamberts, S.W. et al. 1995. Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease: Considerations concerning preoperative medical treatment and the long-term follow-up. J. Clin. Endocrinol. Metab. 80: 3111-3113.
2. Liddle, G.W. et al. 1959. Clinical application of a new test of pituitary reserve. J. Clin. Endocrinol. Metab. 19: 875-894.
3. Newell-Price, J. et al. 1998. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr. Rev. 19: 647-672.
4. Carballeira, A. et al. 1976. Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: Correlation of in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 42: 687-695.
5. Trainer, P.J. & M. Besser. 1994. Cushing's syndrome: Therapy directed at the adrenal glands. Endocrinol. Metab. Clin. N. Amer. 23: 571-584.
6. Verhelst, J.A. et al. 1991 Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin. Endocrinol. (Oxf.) 35: 169-178.
7. Thoren, M. et al. 1985. Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol. (Copenh.) 109: 451-457.
8. Child, D.F. et al. 1976. Drug controlled of Cushing's syndrome: Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol. (Copenh.) 82: 330-341.
9. Nussey, S.S. et al. 1988. The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome. Clin. Endocrinol. (Oxf.) 28: 373-380.
10. Orth, D.N. 1978. Metyrapone is useful only as adjunctive therapy in Cushing's disease. Ann. Intern. Med. 89: 128-130.
11. Jeffcoate, W.J. et al. 1977. Metyrapone in long-term management of Cushing's disease. Br. Med. J. 2: 215-217.
12. Dickstein, G. et al. 1986. Primary therapy for Cushing's disease with metyrapone. JAMA 255: 1167-1169.
13. Donckier, J. et al. 1986. Successful control of Cushing's disease in the elderly with long term metyrapone. Postgrad. Med. J. 62: 727-730.
14. Connell, J.M. et al. 1985. Pregnancy complicated by Cushing's syndrome: Potential hazard of metyrapone therapy: Case report. Br. J. Obstet. Gynaecol. 92: 1192-1195.
15. Santen, R.J. et al. 1983. Site of action of low dose ketoconazole on androgen biosynthesis in men. J. Clin. Endocrinol. Metab. 57: 732-736.
16. Pont, A. et al. 1985. Ketoconazole-induced increase in estradiol-testosterone ratio: Probable explanation for gynecomastia. Arch. Intern. Med. 145: 1429-1431.
17. Engelhardt, D. et al. 1985. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin. Wochenschr. 63: 607-612.
18. Engelhardt, D. et al. 1991 The influence of ketoconazole on human adrenal steroidogenesis: Incubation studies with tissue slices. Clin. Endocrinol. (Oxf.) 35: 163-168.
19. Steen, R.E. et al. 1991 In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol. (Copenh.) 125: 331-334.
20. Mortimer, R.H. et al. 1991 Ketoconazole and plasma and urine steroid levels in Cushing's disease. Clin. Exp. Pharmacol. Physiol. 18: 563-569.
21. Sonino, N. et al. 1991. Ketoconazole treatment in Cushing's syndrome: Experience in 34 patients. Clin. Endocrinol. (Oxf.) 35: 347-352.
22. Tabarin, A. et al. 1991. Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clin. Endocrinol. (Oxf.) 34: 63-69.
23. Chou, S.C. & J.D. Lin. 2000. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr.J. 47: 401-406.
24. Ahmed, M. et al. 2000. ACTH-producing pituitary cancer: Experience at the King Faisal Specialist Hospital & Research Centre. Pituitary 3: 105-112.
25. Rickman, T. et al. 2001. Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. Am. J. Kidney Dis. 37: 838-846.
26. Lewis, J.H. et al. 1984. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases. Gastroenterology 86: 503-513.
27. Stricker, B.H. et al. 1986. Ketoconazole-associated hepatic injury: A clinico-pathological study of 55 cases. J. Hepatol. 3: 399-406.
28. Duarte, P.A. et al. 1984. Fatal hepatitis associated with ketoconazole therapy. Arch. Intern. Med. 144: 1069-1070.
29. Knight, T.E. et al. 1991. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J. Am..Acad. Dermatol. 25: 398-400.
30. Lake-Bakaar, G. et al. 1987. Hepatic reactions associated with ketoconazole in the United Kingdom. Br. Med. J. (Clin. Res. Ed.) 294: 419-422.
31. McCance, D.R. et al. 1987. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1: 573.
32. Tucker, W.S., Jr. et al. 1985. Reversible adrenal insufficiency induced by ketoconazole. JAMA 253: 2413-2414.
33. Miettinen, T.A. 1988. Cholesterol metabolism during ketoconazole treatment in man. J. Lipid Res. 29: 43-51.
34. Dexter, R.N. et al. 1967. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: Studies of the mechanism of action. J. Clin. Endocrinol. Metab. 27: 473-480.
35. Cash, R. et al. 1967. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: Mechanism of action and therapeutic trial. J. Clin. Endocrinol. Metab. 27: 1239-1248.
36. Shaw, M.A. et al. 1988. Aminoglutethimide and ketoconazole: Historical perspectives and future prospects. J. Steroid Biochem. 31: 137-146.
37. Fishman, L.M. et al. 1967. Effects of amino-glutethimide on adrenal function in man. J. Clin. Endocrinol. Metab. 27: 481-490.
38. Misbin, R.I. et al. 1976. Aminoglutethimide in the treatment of Cushing's syndrome. J. Clin. Pharmacol. 16: 645-651.
39. Zachmann, M. et al. 1977. Effect of aminoglutethimide on urinary cortisol and cortisol metabolites in adolescents with Cushing's syndrome. Clin. Endocrinol. (Oxf.) 7: 63-71.
40. Young, R.B. et al. 1973. Complexing of DDT and o,p′-DDD with adrenal cytochrome P-450 hydroxylating systems. J. Steroid Biochem. 4: 585-591.
41. Bergenstal, D.M. et al. 1960. Chemotherapy of adrenocortical cancer with O,p′DDD. Ann. Intern. Med. 53: 672-682.
42. Luton, J.P. et al. 1990. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med. 322: 1195-1201.
43. Southren, A.L. et al. 1961. Effect of O,p′DDD in a patient with Cushing's Syndrome. J. Clin. Endocrinol. Metab. 21: 201-208.
44. Luton, J.P. et al. 1979. Treatment of Cushing's disease by O,p′DDD. Survey of 62 cases. N. Engl. J. Med. 300: 459-464.
45. Haak, H.R. et al. 1991. Prolonged bleeding time due to mitotane therapy. Eur. J. Cancer 27: 638-641.
46. van Seters, A.P. & A.J. Moolenaar. 1991. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol. (Copenh.) 124: 526-533.
47. Maher, V.M. et al. 1992. Possible mechanism and treatment of o,p′-DDD-induced hypercholesterolaemia. Q. J. Med. 84: 671-679.
48. Ledingham, I.M. & I. Watt. 1983. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1: 1270.
49. Weber, M.M. et al. 1993. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin. Invest. 71: 933-938.
50. Lamberts, S.W. et al. 1987. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J. Pharmacol. Exp. Ther. 240: 259-264.
51. De Coster, R. et al. 1985. Effects of etomidate on cortisol biosynthesis in isolated guinea-pig adrenal cells: Comparison with metyrapone. J. Endocrinol. Invest. 8: 199-202.
52. Allolio, B. et al. 1983. Long-term etomidate and adrenocortical suppression. Lancet 2: 626.
53. Allolio, B. et al. 1988. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin. Wochenschr. 66: 361-364.
54. Herrmann, B.L. et al. 2001. [Transsphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an "empty sella" after pretreatment with etomidate]. Dtsch. Med. Wochenschr. 126: 232-234.
55. Drake, W.M. et al. 1998. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J. Clin. Endocrinol. Metab. 83: 3542-3544.
56. Krakoff, J. et al. 2001. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J. Clin. Endocrinol. Metab. 86: 4104-4108.
57. Krieger, D.T. & M. Luria. 1976. Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome. J. Clin. Endocrinol. Metab. 43: 1179-1182.
58. Suda, T. et al. 1983. Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. J. Clin. Endocrinol. Metab. 56: 1094-1099.
59. Waveren Hogervorst, C.O. et al. 1996. Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment. J. Clin. Endocrinol. Metab. 81: 652-655.
60. Tanakol, R. et al. 1996. Cyproheptadine treatment in Cushing's disease. J. Endocrinol. Invest. 19: 242-247.
61. Whitehead, H.M. et al. 1990. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy. Clin. Endocrinol. (Oxf.) 32: 193-201.
62. Sonino, N. et al. 1992. Potential therapeutic effects of ritanserin in Cushing's disease. JAMA 267: 1073.
63. Sonino, N. et al. 2000. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 3: 55-59.
64. Lamberts, S.W. et al. 1980. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J. Clin. Endocrinol. Metab. 51: 307-311.
65. Boscaro, M. et al. 1983. Effect of bromocriptine in pituitary-dependent Cushing's syndrome. Clin. Endocrino.l (Oxf.) 19: 485-491.
66. Mercado-Asis, L.B. et al. 1992. Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol. Jpn. 39: 385-395.
67. Pivonello, R. et al. 1999. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J .Endocrinol. Invest. 22: 860-865.
68. Lamberts, S.W. et al. 1982. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: Differences in the regulation of hormone secretion. J. Clin. Endocrinol. Metab. 54: 286-291.
69. Croughs, R.J. et al. 1989. Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. J. Clin. Endocrinol. Metab. 68: 495-498.
70. de Herder, W.W. & S.W. Lamberts. 1996. Is there a role for somatostatin and its analogs in Cushing's syndrome? Metabolism 45: 83-85.
71. Greenman, Y. & S. Melmed. 1994. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 78: 398-403.
72. Lamberts, S.W. et al. 1989 The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol. (Copenh.) 120: 760-766.
73. Bertagna, X. et al. 1989. Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide. J. Clin. Endocrinol. Metab. 68: 988-991.
74. Vignati, F. & P. Loli. 1996. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J. Clin. Endocrinol. Metab. 81: 2885-2890.
75. Koppeschaar, H.P. et al. 1983. Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease. Acta Endocrinol. (Copenh.) 104: 160-163.
76. Beckers, A. et al. 1990. Cyclical Cushing's disease and its successful control under sodium valproate. J. Endocrinol. Invest. 13: 923-929.
77. Gomi, M. et al. 1985. Unaltered stimulation of pituitary adrenocorticotrophin secretion by corticotrophin-releasing factor following sodium valproate administration in a patient with Nelson's syndrome. Clin. Endocrinol. (Oxf.) 23: 123-127.
78. Colao, A. et al. 1997. Failure of long-term therapy with sodium valproate in Cushing's disease. J. Endocrinol. Invest. 20: 387-392.
79. Baulieu, E.E. 1991 The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications. Endocrinol. Metab. Clin. N. Amer. 20: 873-891.
80. Healy, D.L. et al. 1985. Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: Dose response relationships. J. Clin. Endocrinol. Metab. 60: 1-4.
81. Bertagna, X. et al. 1984. The new steroid analog RU 486 inhibits glucocorticoid action in man. J. Clin. Endocrinol. Metab. 59: 25-28.
82. Nieman, L.K. et al. 1985. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 61: 536-540.
83. Bertagna, X. et al. 1986. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J. Clin. Endocrinol. Metab. 63: 639-643.
84. Sartor, O. & G.B.Cutler, Jr. 1996 Mifepristone: Treatment of Cushing's syndrome. Clin. Obstet. Gynecol. 39: 506-510.
85. Trainer, P.J. et al. 1993. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin. Endocrinol. (Oxf.) 39: 441-443.
86. Lacroix, A. et al. 1992 Gastric inhibitory polypeptide-dependent cortisol hypersecretion: A new cause of Cushing's syndrome. N. Engl. J. Med. 327: 974-980.
87. Lacroix, A. et al. 2000 The diversity of abnormal hormone receptors in adrenal Cushing's syndrome allows novel pharmacological therapies. Braz. J.Med. Biol. Res. 33: 1201-1209.
88. Paez-Pereda, M. et al. 2001 Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. 108: 1123-1131.